AbbVie is dedicated to advancing cutting-edge science and technologies with the potential to create groundbreaking therapies in fields that strategically align with areas of interest.

Target partnership meetings will include both formed and aspiring biotech companies that are actively developing next-generation drug modalities, including small molecules, biologics, gene therapies, in-vivo cell therapies, and platform technologies.

The specific therapeutic areas of interest include:

• Oncology
• Immunology
• Neuroscience
• Eye Care
• Genetic Medicines (RNA & DNA, Delivery and Cargo)

Exclusions: Diagnostics, Devices, Research Tools, Nutrition, and Healthcare Services/IT

AVM is the wholly-owned venture capital organization within Astellas, dedicated to supporting pre-clinical, cutting-edge science that can bring VALUE to patients.

For over 15 years, AVM has provided equity investments to private, early-stage companies developing therapeutic programs and platform technologies, helping them to advance their innovations faster. AVM is a strategic investor, making investments in science that will enhance the current Astellas R&D pipeline or that could catalyze new directions in discovery research.

The Boehringer Ingelheim Venture Fund is the strategic venture fund of the Boehringer Ingelheim Corporation.

Prioritizing early-stage, typically Seed, investment opportunities and/or company formation for first-in-class therapeutic approaches. Indication areas of specific interest currently are immuno-oncology, regenerative medicine and antigen-specific tolerance. Medical devices, care logistics solutions out of scope.

Chiesi Global Rare Diseases (“Chiesi GRD”) is a business unit of the Chiesi Group, a family business striving to create a world where it is common to have a therapy for all diseases while acting as a force for good, for society and the planet.

Chiesi GRD is interested in partnering with startups working on cutting edge technologies with rare-disease applications. Specifically, we are looking for pioneers in gene editing therapies, and novel delivery technologies that can enable these therapies to be used in-vivo. Our core indication areas are hematology, immunology, ophthalmology, dermatology, metabolic or inborn errors of metabolism, especially lysosomal storage diseases.

Civilization Ventures is an early stage biotech investment firm focused on supporting founders build category-defining technologies to tackle the most critical challenges in biology and healthcare.

We champion founders who take on the most important challenges in biology and health care, providing them with the capital and resources to succeed. We call our approach “mentor capital”. We’re here to foster your growth as a founder to help you build tomorrow’s generational company.

Our investment thesis is focused on innovations across genomics + diagnostics, digital health, and synthetic biology. Our portfolio includes category-defining companies in AI and liquid biopsy-based technologies, gene editing, value-based care and cell therapies.

Codon Capital invests in West Coast pre-clinical therapeutics and synthetic biology startups.

Codon has invested in serial entrepreneurs four times in a row and fresh from academic founder first time CEOs. Scientists are great problem solvers, so lets go after tough problems with technology that allows us to iterate to overcome the obstacles blocking every great invention.

Investment: typically early stage from Seed to A in therapeutics, tools/dx.

We chose to name our firm LDV Partners in honor of Leonardo Da Vinci. As one of history’s greatest innovators, Da Vinci inspired Europe’s cultural Renaissance. As Silicon Valley and many parts of the globe flourishes in a Technology Renaissance that is impacting every market globally, the LDVP team seeks to partner with talented entrepreneurs working on disruptive technologies and innovative business models to build a world-class company.

Our investment focus includes pre-clinical and clinical stage drug development companies exploring the underlying molecular and cellular mechanisms of aging; early-stage companies developing new solutions to enable personalized medicine and advanced diagnostics; foundational platform technologies and integrated healthcare solutions enabling faster drug discovery and testing at scale.

LongeVC is an international venture capital firm investing in an ageless future. Through supporting exceptional early stage founders, our mission is to bring breakthrough biotech to market — the science that will change lives and transform our health.

Remiges Ventures (RV) is an early stage, therapeutics only venture capital company.

We typically take a lead position for the syndication of early stage investment rounds globally. RV team is connected with KOLs in various therapeutic areas, serial entrepreneurs, key consultants and pharma BD people. We the Remiges team actively participate in the value creation for its portfolio companies. We seek innovative therapeutics projects that address unmet patient needs with the potential to change clinical practice and efficacy or patient outcomes. We are therapy area and modality agnostic.

Servier is a global pharmaceutical group governed by a Foundation that aspires to have a meaningful impact for patients.

As a leader in oncology, Servier is committed to finding solutions that will address today’s challenges in hard-to-treat indications such as hematological, brain and gastrointestinal malignancies. Servier is also focused on expanding its therapeutic areas into neurological diseases where accurate patient profiling makes it possible to offer a targeted therapeutic response through precision medicine. To address these areas of unmet need, Servier has prioritized small molecule, oligonucleotide and antibody-based approaches. To learn more about our interests, see our partnering page.